Skip to content

A randomised controlled trial comparing the clinical and cost-effectiveness of the Avaulta anterior mesh and the standard anterior colporraphy for the primary surgical treatment of a cystocele stage >= 2

A randomised controlled trial comparing the clinical and cost-effectiveness of the Avaulta anterior mesh and the standard anterior colporraphy for the primary surgical treatment of a cystocele stage >= 2 - Avaulta versus anterior colphorraphy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30439
Enrollment
115
Registered
2007-02-20
Start date
2007-05-23
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cystocele vaginal prolapse

Interventions

Women are either allocated to a group who will undergo a classic anterior colporraphy repair or a group in which the Avaulta® mesh is used.

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Women aged 40-80 years Cystocele stage >= 2 according to POP Q classification No previous anterior colporraphy Good understanding of Dutch language in word en writing

Exclusion criteria

Exclusion criteria: 1. Women with childbearing potential who do not use adequate contraceptive measures (hormonal contraceptives, barrier methods (condoms), intra uterine device, male vasectomy, sterilisation). 2. History of major gynaecological or urological surgery, with the exception of a hysterectomy for reasons other than a genital prolapse. 3. History of cancer or severe cardiopulmonary disease 4. Conditions that might interfere with a successful conduction and completion of the study in the opinion of the specialist (language problems, cognitive dysfunction, etc) 5. Recurrent lower urinary tract infections (> 3 culture proven infections/year) 6. Maximum bladder capacity

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study is the number of women who will have a recurrence, defined as a stage >= 2 anterior vaginal prolapse at 2 years follow-up.

Secondary

MeasureTime frame
Secondary endpoints are; - The effect of surgery on urogenital symptoms and quality of life - Complications of surgery (direct and medium term) - Cost-effectiveness analysis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)